Status:
COMPLETED
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Ariad Pharmaceuticals
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety, tolerability, and recommended phase 2 dose of oral ridaforolimus administered in combination with intravenous bevacizumab in patients with advanced c...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Advanced or metastatic solid tumor malignancy
- ECOG performance status of less than or equal to 1
- Life expectancy of greater than 3 months
- At least 4 weeks must have elapsed between prior investigational therapy, chemotherapy, or radiotherapy, and the first dose of deforolimus
- Adequate hematological, hepatic and renal function
- Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL
- Signed informed consent
- Women of childbearing potential must have a negative serum pregnancy test within 7 days of starting therapy and must use an approved contraceptive method from time of screening until 30 days after the last dose of study drug
Exclusion
- Tumor location in close proximity to a major blood vessel
- History of brain metastases, spinal cord compression, or carcinomatous meningitis. Primary brain tumors (for example, glioblastoma) are allowed.
- New brain metastases, spinal cord compression, or leptomeningeal metastases on screening CT scan or MRI
- Hemoptysis or hematemesis within 28 days prior to entering the trial
- Clinical significant unexplained bleeding within 28 days prior to entering the trial
- Uncontrolled hypertension
- Proteinuria at screening
- Clinically significant cardiovascular disease
- Newly diagnosed or poorly controlled type 1 or 2 diabetes
- Active infection requiring prescribed intervention
- Other concurrent illness that, in the Investigator's judgement, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug
- Major surgery within 28 days before trial entry, or any incompletely healed surgical incision; minor surgery or procedures within 7 days
- Pregnant or breastfeeding
- Known allergy to macrolide antibiotics
- Known hypersensitivity to any component of bevacizumab
- Concurrent treatment with medications that strongly induce or inhibit cytochrome P450 (CYP3A)
- Known history of HIV sero-positivity
- Any condition in the Investigator's judgement that renders the patient unable to fully understand and provide informed consent and/or comply with the protocol
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00781846
Start Date
October 1 2008
End Date
February 1 2010
Last Update
February 13 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.